Women with previous pregnancy loss taking LDA had more human chorionic gonadotropin-detected pregnancies and live births<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Jan. 26, 2021 (HealthDay News) — Adherence to a low-dose aspirin (LDA) regimen improves pregnancy outcomes for women with previous pregnancy loss, according to a study published online Jan. 26 in the Annals of Internal Medicine<\/em>.<\/p>\n Ashley I. Naimi, Ph.D., from Emory University in Atlanta, and colleagues estimated the per-protocol effects of preconception-initiated LDA on pregnancy loss and live birth in a prospective cohort involving 1,227 women aged 18 to 40 years with one or two previous pregnancy losses who were attempting pregnancy.<\/p>\n The researchers found that for every 100 women in the trial, adhering to LDA for five of seven days per week led to eight more human chorionic gonadotropin-detected pregnancies, 15 more live births, and six fewer pregnancy losses relative to placebo. Furthermore, postconception initiation of LDA therapy led to a reduction in the estimated effects compared with placebo. These effects were obtained with adherence to a minimum of four of seven days per week.<\/p>\n “Early adoption of LDA with maximal daily adherence promoted pregnancy and live birth and protected against pregnancy loss in women trying to become pregnant after a history of pregnancy loss,” the authors write. “Efforts geared toward improving daily adherence to LDA may yield improvements in aspirin’s effectiveness on reproductive outcomes for women trying to conceive.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n